Echinacoside Improves Pulmonary Vascular Remodeling by Regulating the L- and T-Type Ca2+ Channels in the Prevention and Treatment of Pulmonary Hypertension

8 January 2026

Yuefu Zhao, Jinyu Wang, Yujie Qiao, Xiangyun Gai, Jiacheng Hu, Hongmai Wang, Qingqing Xia, Qiuqin Hu, Zhanqiang Li, Cen Li, Hongtao Bi

https://doi.org/10.1002/pul2.70235

Abstract

The typical pathology of pulmonary hypertension (PH) is characterized by pulmonary vasoconstriction and irreversible pulmonary vascular remodeling. Vascular remodeling is the process of structural changes and cellular rearrangement of blood vessels due to injury and is a significant factor in conditions such as PH. Echinacoside (ECH) is a phenylethanol glycoside from Tibetan herbs, and our previous study found that ECH modulated calcium channels on pulmonary artery smooth muscle cells (PASMCs) and improved pulmonary vasoconstriction. To investigate the role of ECH in improving pulmonary vascular remodeling in PH, we constructed hypoxia-induced hypoxic pulmonary hypertension (HPH) and MCT-induced pulmonary arterial hypertension (PAH) models. Transcriptomic analysis revealed significant enrichment of Cav1.2, Cav3.2, and PKC/MAPK signaling pathways in PAH rats. ECH effectively inhibited Cav1.2 and Cav3.2 protein and mRNA expression, as well as the phosphorylation levels of PKC/MAPK, in HPH and PAH. In addition, ECH effectively reduced mean pulmonary artery pressure (mPAP) and right ventricular hypertrophy index (RVHI) and improved pulmonary vascular remodeling in HPH and PAH rats. In short, we found that ECH improved pulmonary vascular remodeling by modulating Cav1.2 and Cav3.2/PKC/MAPK pathways. Furthermore, this improvement was effective in both HPH and PAH.

Read the full research article

Other materials on this topic

19 December 2025

Pulmonary Hypertension Community Call — December

An on-demand recording of PVRI’s December PH Community Call, featuring informal discussion on emerging science and patient-focused research in pulmonary hypertension. The session covers new insights into hypoxic PH mechanisms and exercise interventions in PAH, with expert-led moderation and open exchange.

PVRI Community Calls

12 December 2025

Living Legend: Rubin Tuder, University of Colorado

In this Living Legends in PH session, Rubin Tuder reflects on a career that has shaped modern pulmonary hypertension research. He discusses key scientific advances, including the Sugen–hypoxia rat model, and shares personal insights on discovery, mentorship, and the evolution of the PH field, joined by Paul Hassoun and Jason Hong.

Members Only

2 December 2025

Identification of Diagnostic Biomarkers Causally Associated With Gut Microbiota and Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a pulmonary disease associated with alterations in gut microbiota. We aimed to identify potential diagnostic genes causally associated with gut microbiota and PAH.

Pulmonary Circulation

1 December 2025

Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension

In the recent paper, Pulmonary Vascular Compromise is Associated with Survival in Pediatric Pulmonary Hypertension: a New Computational Model by Niccum et al. [1] presents an innovative computational model reframing pulmonary vascular disease through the concept of pulmonary vascular compromise (PVC), a quantifiable estimate of the proportion of pulmonary vascular surface area lost relative to an idealized normal pulmonary vascular capacity.